HYPASE Trademark

Trademark Overview

On Friday, September 13, 2024, a trademark application was filed for HYPASE with the United States Patent and Trademark Office. The USPTO has given the HYPASE trademark a serial number of 98749357. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, June 18, 2025. This trademark is owned by WUXI BIOLOGICS IRELAND LIMITED. The HYPASE trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

processing and treating of chemical reagents, namely, the custom manufacture of chemical reagents; custom manufacturing of antibody drugs; processing of biomedical preparations, namely, the custom manufacture of biopharmaceutical preparations; processing of pharmaceutical preparations, namely, the custom manufacture of pharmaceuticals preparations; custom manufacturing of pharmaceuticals; custom manufacture of biopharmaceuticals

Consulting services in the field of technological product development; research and development of new products for others; research and development of new products; scientific research and development; pharmaceutical drug development services; pharmaceutical research services; biochemical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies; biomedical research services
hypase

General Information

Serial Number98749357
Word MarkHYPASE
Filing DateFriday, September 13, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, June 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesprocessing and treating of chemical reagents, namely, the custom manufacture of chemical reagents; custom manufacturing of antibody drugs; processing of biomedical preparations, namely, the custom manufacture of biopharmaceutical preparations; processing of pharmaceutical preparations, namely, the custom manufacture of pharmaceuticals preparations; custom manufacturing of pharmaceuticals; custom manufacture of biopharmaceuticals
Goods and ServicesConsulting services in the field of technological product development; research and development of new products for others; research and development of new products; scientific research and development; pharmaceutical drug development services; pharmaceutical research services; biochemical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibodies; biomedical research services

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateFriday, September 13, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 13, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameWUXI BIOLOGICS IRELAND LIMITED
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCOUNTY LOUTH A91X56F
IE

Trademark Events

Event DateEvent Description
Friday, September 13, 2024NEW APPLICATION ENTERED
Friday, January 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 13, 2025ASSIGNED TO EXAMINER
Monday, March 24, 2025NON-FINAL ACTION E-MAILED
Monday, March 24, 2025NON-FINAL ACTION WRITTEN
Monday, March 24, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 18, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 18, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 18, 2025TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

hypase development research custom services preparations pharmaceutical manufacture namely processing products